Rezolute (NASDAQ:RZLT) Upgraded at Craig Hallum

Key Points

• Craig Hallum upgraded Rezolute to “buy” from “hold” and raised its price target to $7 from $4, implying approximately 67% upside from the stock’s $4.18 opening price.
• Analyst sentiment is broadly positive: Rezolute has a consensus “Moderate Buy” rating and an average price target of $10.62, although one analyst recently issued a “sell” rating.
• Rezolute remains unprofitable, reporting quarterly EPS of negative $0.20 versus expectations of negative $0.15. The clinical-stage biotech is developing RZ358, a potential treatment for congenital hyperinsulinism, while institutional investors own nearly 83% of its shares.

Rezolute (NASDAQ:RZLT - Get Free Report) was upgraded by analysts at Craig Hallum from a "hold" rating to a "buy" rating in a research note issued on Tuesday, Benzinga reports. The firm presently has a $7.00 price target on the stock, up from their prior price target of $4.00. Craig Hallum's price objective suggests a potential upside of 67.46% from the company's current price.

RZLT has been the subject of a number of other reports. Guggenheim lifted their price objective on shares of Rezolute from $6.00 to $11.00 and gave the stock a "buy" rating in a research note on Monday, June 15th. HC Wainwright lifted their price target on Rezolute from $5.00 to $10.00 and gave the stock a "buy" rating in a research report on Friday. Wall Street Zen cut Rezolute from a "hold" rating to a "sell" rating in a research note on Tuesday, June 30th. Citizens Jmp upgraded Rezolute from a "market perform" rating to an "outperform" rating and set a $11.00 price objective on the stock in a research report on Wednesday, June 3rd. Finally, Wedbush raised their price objective on Rezolute from $5.00 to $6.00 and gave the company an "outperform" rating in a research note on Wednesday, June 3rd. Ten investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $10.62.

Rezolute Price Performance

NASDAQ:RZLT opened at $4.18 on Tuesday. The company has a market cap of $404.29 million, a price-to-earnings ratio of -5.50 and a beta of 0.60. Rezolute has a 1 year low of $1.07 and a 1 year high of $11.46. The stock's 50 day simple moving average is $4.57 and its two-hundred day simple moving average is $4.03.

Rezolute (NASDAQ:RZLT - Get Free Report) last posted its earnings results on Thursday, September 24th. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.05). As a group, analysts anticipate that Rezolute will post -0.52 EPS for the current year.

Institutional Trading of Rezolute

Institutional investors have recently added to or reduced their stakes in the company. Jennison Associates LLC bought a new position in shares of Rezolute during the first quarter valued at approximately $10,489,000. Siren L.L.C. purchased a new position in Rezolute during the 1st quarter valued at $10,151,000. Dimensional Fund Advisors LP grew its position in Rezolute by 273.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 530,229 shares of the company's stock valued at $1,617,000 after acquiring an additional 388,346 shares during the last quarter. Knott David M Jr increased its stake in Rezolute by 8.8% in the first quarter. Knott David M Jr now owns 370,000 shares of the company's stock worth $1,128,000 after purchasing an additional 30,000 shares during the period. Finally, Bank of New York Mellon Corp purchased a new stake in Rezolute in the second quarter worth $1,104,000. Institutional investors own 82.97% of the company's stock.

Trending Headlines about Rezolute

Here are the key news stories impacting Rezolute this week:

• Positive Sentiment: HC Wainwright projects Rezolute could reach positive earnings of $1.42 per share in fiscal 2030 and $2.94 per share in fiscal 2031, substantially improving the company’s long-term earnings potential.
• Positive Sentiment: The firm raised its fiscal 2029 EPS forecast to a loss of $0.14 from a loss of $0.17, while maintaining its Buy rating and $10 price target—well above recent trading levels.
• Neutral Sentiment: HC Wainwright expects Rezolute to remain unprofitable through fiscal 2029, with estimates of a $0.57-per-share loss in fiscal 2027, a $0.34 loss in fiscal 2028, and a $0.14 loss in fiscal 2029. The analyst forecasts a return to positive quarterly earnings in the fourth quarter of 2028.
• Negative Sentiment: The analyst lowered its fiscal 2027 EPS forecast to a $0.57 loss from $0.45, cut fiscal 2028 to a $0.34 loss from $0.33, and reduced estimates for the first two quarters of fiscal 2027 and the fourth quarter of fiscal 2027. These revisions point to higher expected near-term losses and may limit the stock’s upside until Rezolute’s pipeline generates revenue.

About Rezolute

Rezolute, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for rare and metabolic diseases. The company's research is centered on therapies that address abnormal insulin activity and other conditions involving disrupted glucose regulation.

Rezolute's leading product candidate is RZ358, an investigational monoclonal antibody designed to reduce the effects of excessive insulin. The therapy is being developed primarily for congenital hyperinsulinism, a rare disorder in which the pancreas produces too much insulin and causes potentially severe, recurrent hypoglycemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.